Last update 15 Dec 2025

SC-0191

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SC 0191, SC0191
Target
WEE1
Action
inhibitors
Mechanism
WEE1 inhibitors(Serine/threonine-protein kinase WEE1 inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Metastatic Colorectal CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent ovarian cancer+ [3]
Inactive Indication
Advanced Malignant Solid Neoplasm
Originator Organization
Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.
Active Organization
Wuxi Zhikang Hongyi Biological Technology Co LtdWuxi Zhikang Hongyi Biological Technology Co LtdFudan UniversityFudan University
Inactive Organization
Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with SC-0191
NCT06363552
/ Not yet recruitingPhase 2IIT
A Study to Evaluate the Preliminary Safety and Efficacy of SC0191 as Single Agent or in Combination With Bevacizumab or 5-FU/LV in Advanced Colorectal Cancer
NCT06055348
/ Not yet recruitingPhase 1/2
A Phase Ib/II Clinical Study on the Safety, Pharmacokinetic Characteristics, and Preliminary Efficacy of SC0191 Combination Chemotherapy in Patients With Advanced Ovarian Cancer.
CTR20210649
/ TerminatedPhase 1
一项开放、单臂的I期临床研究：评价SC0191片在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征和药效动力学特征，并初步探索SC0191片的抗肿瘤活性
[Translation] An open, single-arm Phase I clinical study: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of SC0191 tablets in patients with advanced malignant solid tumors, and to preliminarily explore the anti-tumor activity of SC0191 tablets
100 Clinical Results associated with SC-0191
Login to view more data
100 Translational Medicine associated with SC-0191
Login to view more data
100 Patents (Medical) associated with SC-0191
Login to view more data
100 Deals associated with SC-0191
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
China
-01 May 2024
Platinum-Resistant Ovarian CarcinomaPhase 2-
Wuxi Zhikang Hongyi Biological Technology Co LtdWuxi Zhikang Hongyi Biological Technology Co Ltd
30 Oct 2023
Recurrent ovarian cancerPhase 2
China
Wuxi Zhikang Hongyi Biological Technology Co LtdWuxi Zhikang Hongyi Biological Technology Co Ltd
07 Aug 2023
Solid tumorPhase 2
United States
Wuxi Zhikang Hongyi Biological Technology Co LtdWuxi Zhikang Hongyi Biological Technology Co Ltd
20 Feb 2023
Uterine Serous CarcinomaPhase 1
China
Wuxi Zhikang Hongyi Biological Technology Co LtdWuxi Zhikang Hongyi Biological Technology Co Ltd
30 Jan 2022
Advanced Malignant Solid NeoplasmPhase 1
China
Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.
25 Jun 2021
Colorectal CancerPreclinical
China
Fudan UniversityFudan University
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free